Boston, MA 03\/31\/2014 (wallstreetpr) \u2013 U.S based, Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)<\/b>, has announced it has received Food and Drug Administration FDA approval for additional bulk manufacturing suite, involving its product EXPARELL,a bupivacaine injectable liposome suspension. The suite is currently being housed at the company\u2019s Science center in San Diego where EXPARELL is also being manufactured.<\/p>\n
The approval of EXPAREL for Suite C manufacturing suite, marks another milestone for the company as the expansion of manufacturing capacity will allow it meet its growing demand in the industry. The product can be used as a multimodal pain management regimen especially for people who would wish to reduce or cut the use of narcotics. The product has been tested and proved to be effective in decreasing narcotic related events especially after withdrawal from narcotics.<\/p>\n
EXPAREL Passes Medical Tests<\/b><\/p>\n
The approval by the FDA comes after the company carried out successful phase III safety and efficacy studies in which the product passed. Phase III study was carried on 183 studies where random patients received 266mg of EXPAREL or placebo, the patients were also offered rescue narcotics rescue whenever needed.<\/p>\n
\u00a0The tests produced statistical significance in favor of EXPAREL compared to placebo. EXPAREL utilizes Pacira proprietary technology DepoFoam which is a unique platform that encapsulates drugs without changing their structure<\/p>\n
Yvonne Greenstreet Appointed to the company\u2019s board<\/b><\/p>\n
The approval of EXPAREL for suite C manufacture comes at the back of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) <\/b>appointing Yvonne Greenstreet into the company\u2019s board. Dr. Yvonne comes into the board with 20 years of experience in the pharmaceutical industry, sure to impact Pacira business activities.<\/p>\n
Dr. Yvonne comes with a proven track record of as an established business leader as well as a competent drug developer. She comes at the helm having acquired FDA approval as well as equivalent regulatory bodies across the U.K and EU.<\/p>\n
Yvonne Past Experience<\/b><\/p>\n
Previously, Dr. Yvonne was the senior vice president and head of medicines at Pfizer Inc.(NYSE:PFE)<\/strong> where she is accredited to have overseen a $16 billion specialty business which included immune inflammation, vaccine and rare diseases cases.<\/p>\n Dr. Greenstreet was selected for the top post due to her ability to identify emerging opportunities through her expertise in drug development, which should be of great help to Pacira going forward. She is a trained physician having earned her medical degree from Leeds University in the U.K.<\/p>\n","protected":false},"excerpt":{"rendered":" Boston, MA 03\/31\/2014 (wallstreetpr) \u2013 U.S based, Pacira Pharmaceuticals Inc. (NASDAQ:PCRX), has announced it has received Food and Drug Administration FDA approval for additional bulk […]<\/p>\n","protected":false},"author":13,"featured_media":18370,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5698,993,5697,2745],"stock_ticker":[],"class_list":["post-18369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqpcrx","tag-nysepfe","tag-pacira-pharmaceuticals-inc-nasdaqpcrx","tag-pfizer-inc-nysepfe","entry"],"acf":[],"yoast_head":"\n